LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals Inc (LBRX)
Company Research
Source: GlobeNewswire
Pivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled “Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults with Acute Schizophrenia: A Phase 2 Randomized Clinical Trial.” LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT-7 receptors that is being advanced as a potential first benzamide in the U.S. for the treatment of neuropsychiatric disorders. “We are plea
Show less
Read more
Impact Snapshot
Event Time:
LBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBRX alerts
High impacting LB Pharmaceuticals Inc news events
Weekly update
A roundup of the hottest topics
LBRX
News
- LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham [Yahoo! Finance]Yahoo! Finance
- LB Pharmaceuticals (LBRX) is now covered by Craig Hallum. They set a "buy" rating and a $36.00 price target on the stock.MarketBeat
- LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
LBRX
Earnings
- 3/26/26 - In-Line
LBRX
Sec Filings
- 4/23/26 - Form ARS
- 4/23/26 - Form DEF
- 4/23/26 - Form DEFA14A
- LBRX's page on the SEC website